The Drug Development Process
- How HIV Drugs Get Approved (August 9, 2012)
To read PDF, click here.
From AIDS InfoNet
- Product Development Partnerships "Essential" in Fight Against Global Diseases (December 2, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
 A Golden Decade of Antiretroviral Drug Development (Fall 2011)
Success rate for new ARVs entering phases II-III surpassed 32% from 2003-2011; U.S. ADAP prescribing practices closely match recent ARV guidelines.
To read PDF, click here.
In TAGline, from Treatment Action Group
- Nature News Explores Proposal for Public-Private Partnership to Speed Drug Development (February 15, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- GlaxoSmithKline, Pfizer Formally Launch Company to Develop New HIV Treatments (November 3, 2009)
Two of the major pharmaceutical companies producing HIV meds have launched a new joint company focused solely on HIV: ViiV Healthcare.
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Medical Innovation and Patent Gridlock (June 20, 2005)
John James with a different take on why patents tend to stifle innovation in drug development.
In AIDS Treatment News, from AIDS Treatment News
- Truvánadu: Does Gilead's Famed 903 Study Really Show You What They Tell You It Shows? (December 2004)
A highly critical examination of the manner in which many clinical trials are designed.
In TAGline, from Treatment Action Group
On TheBodyPRO.com
- Smarter Clinical Trials for Faster Drug Development (August 23, 2004)
Experimental drugs are being tested in humans earlier in the development process, which can help speed the drugs' progress -- or their demise.
In AIDS Treatment News, from AIDS Treatment News
- Prominent Medical Group Calls for Full Disclosure on Drug Studies (June 16, 2004)
The American Medical Association proposes a national registry to prevent U.S. pharmaceutical companies from hiding negative clinical trial results.
In Boston Globe
- Abbott's Norvir Price Hike Is Bad Medicine (May/June 2004)
Bob Huff explains why the December 2003 ritonavir price increase may well doom the development of boosted protease inhibitors.
In GMHC Treatment Issues, from Gay Men's Health Crisis
VIEW ALL ARTICLES
|
Advertisement
|
Email
Glossary
